A sub-analysis of the ROCKET-AF trial showed that patients with atrial fibrillation who took the new anticoagulant rivaroxaban to prevent stroke were 40% less likely to have intracranial hemorrhages than warfarin users. Researchers also found that adding clopidogrel to either warfarin or rivaroxaban increased the risk of intracranial bleeding by 250% compared with clopidogrel or warfarin alone.
Study: Intracranial bleeding risk lower in rivaroxaban users
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||